ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis
NANot yet recruitingINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
July 1, 2025
Primary Completion Date
July 1, 2027
Study Completion Date
July 1, 2028
Conditions
Urolithiasis
Interventions
DIETARY_SUPPLEMENT
tributyrin
tributyrin (875 mg, BID)
Trial Locations (1)
V5Z1M9
Vancouver General Hospital, Vancouver
All Listed Sponsors
lead
University of British Columbia
OTHER
NCT07004257 - ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis | Biotech Hunter | Biotech Hunter